NDAINTRAVENOUSSOLUTION
Approved
Dec 2014
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
15
Data completeness
5/8 — Partial
RAPIVAB (peramivir) by BioCryst Pharmaceuticals is neuraminidase inhibitors [moa]. Approved for influenza. First approved in 2014.
Drug data last refreshed Yesterday
Mechanism of Action
Neuraminidase Inhibitors
Pharmacologic Class:
Neuraminidase Inhibitor
Indications (1)
Clinical Trials (15)
Safety, PK and Effectiveness of IV Peramivir in Elderly and Higher Risk Subjects With Uncomplicated Influenza
Started Dec 2015
74 enrolled
Influenza
ED Influenza Therapeutic Pilot Study: Oseltamivir vs. Peramivir
Started Nov 2015
180 enrolled
Influenza
Safety, PK and Effectiveness of IV Peramivir Versus Oseltamivir in Pediatric Subjects With Uncomplicated Influenza
Started Mar 2015
137 enrolled
Influenza
Peramivir Treatment Response in Adults Hospitalized for Influenza-associated Lower Respiratory Tract Infections
Started Feb 2011
16 enrolled
Influenza
A Study to Evaluate the Efficacy and Safety of Intravenous Peramivir in Subjects With Uncomplicated Influenza.
Started Oct 2010
1 enrolled
Influenza
Worked on RAPIVAB at BioCryst Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.